Datroway Gains EU Nod as First-Line TNBC Treatment with Survival Benefit
Event summary
- Datroway® (datopotamab deruxtecan) approved in the EU for first-line treatment of metastatic TNBC patients ineligible for immunotherapy.
- Approval based on TROPION-Breast02 trial showing 5.0-month median overall survival improvement vs. chemotherapy.
- Datroway reduced risk of disease progression or death by 43% compared to chemotherapy.
- EU approval follows U.S. approval in May 2026 and ongoing reviews in China, Japan, Australia, Canada, Singapore, and Switzerland.
The big picture
This approval solidifies Datroway as a key player in the TNBC treatment landscape, addressing a critical unmet need for patients ineligible for immunotherapy. The success of this TROP2-directed ADC underscores the growing importance of targeted therapies in oncology and highlights Daiichi Sankyo’s strategic focus on its DXd antibody drug conjugate platform.
What we're watching
- Market Penetration
- The pace at which Datroway gains market share in the EU and other regions under review.
- Competitive Dynamics
- How this approval positions Daiichi Sankyo and AstraZeneca against existing TNBC treatments.
- Pipeline Expansion
- The progress of other DXd ADCs in Daiichi Sankyo’s pipeline, particularly those in collaboration with Merck & Co.
Related topics